Scarica l'app Stockscreener
1.35
4.26%
-0.06
Dopo l'orario di chiusura:
1.35
Precedente Chiudi:
$1.41
Aprire:
$1.41
Volume 24 ore:
684.32K
Relative Volume:
0.79
Capitalizzazione di mercato:
$82.96M
Reddito:
$248.00K
Utile/perdita netta:
$-149.34M
Rapporto P/E:
-0.5545
EPS:
-2.4348
Flusso di cassa netto:
$-128.71M
1 W Prestazione:
+1.50%
1M Prestazione:
+21.62%
6M Prestazione:
-15.09%
1 anno Prestazione:
-11.18%
Intervallo 1D:
$1.3103
$1.435
Intervallo di 1 settimana:
$1.29
$1.435
Portata 52W:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.35 | 82.96M | 248.00K | -149.34M | -128.71M | -2.4348 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Downgrade | Needham | Buy → Hold |
| 2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
| 2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-05-18 | Iniziato | Canaccord Genuity | Buy |
| 2023-04-13 | Iniziato | Robert W. Baird | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-07 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Outperform |
| 2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-20 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Cowen | Outperform |
| 2020-06-29 | Iniziato | Needham | Buy |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
Pliant Therapeutics (PLRX): Canaccord Genuity Adjusts Price Targ - GuruFocus
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - TipRanks
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Issues Quarterly Earnings Results - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
PLRX: PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - TipRanks
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PLRX: Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2 - TradingView
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT) - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - The Manila Times
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investment Recap: What is the Moat Score of Pliant Therapeutics IncJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
PLRX Should I Buy - Intellectia AI
Should I hold or sell Pliant Therapeutics Inc. stock in 20252025 Winners & Losers & Short-Term Swing Trade Alerts - mfd.ru
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant - Stock Titan
PLRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Chart Watch: What is Pliant Therapeutics Inc.’s book value per shareEarnings Growth Report & Weekly High Potential Stock Alerts - mfd.ru
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January - MarketBeat
Idiopathic Pulmonary Fibrosis Market: Expanding Revenue - openPR.com
Aug Analyst Calls: Is GENC on track to beat earningsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Portfolio Shifts: Is Pliant Therapeutics Inc. a potential multi baggerJuly 2025 Levels & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Weekly Earnings: How cyclical is Pliant Therapeutics Incs revenue streamExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
Breakout Zone: Why is Pliant Therapeutics Inc stock going upJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Reduce” from Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus
Quarterly Earnings: Is Pliant Therapeutics Inc a stock for growth or value investorsJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
What’s the beta of Pliant Therapeutics Inc. stockQuarterly Trade Report & Entry Point Confirmation Signals - mfd.ru
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares By Investing.com - Investing.com UK
Pliant Therapeutics CHRO Cheung sells $9.6k in stock By Investing.com - Investing.com Nigeria
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics CHRO Cheung sells $9.6k in stock - Investing.com
Pliant therapeutics CFO Cummings sells $30,722 in stock By Investing.com - Investing.com Canada
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):